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Alterations in cyclic nucleotide phosphodiesterase
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Objective: To elucidate the activity and expression of cyclic nucleotide phosphodiesterase (PDE) families in omental (OM) and
subcutaneous (SC) adipose tissue and adipocytes, and to study alterations in their activity in human obesity.
Design: Cross-sectional, translational research study.
Patients: In total, 25 obese and 9 non-obese subjects undergoing gastrointestinal surgery participated in the study.
Results: Inverse correlations between PDE activities and body mass index (BMI) were seen in both SC and OM adipose tissue.
Inverse correlations between total PDE and PDE3 activity and BMI were seen in OM adipocytes but not in SC adipocytes. In both
SC and OM adipose tissue of obese patients, total PDE and PDE3 activities were decreased compared with the controls. In SC
adipose tissue of Type 2 diabetes (T2D) patients, the PDE activity not inhibitable by PDE3 or PDE4 inhibitors (PDEn) was
increased compared with obese non-diabetic patients. In addition to PDE3 and 4 isoforms, PDE7B, PDE9A and PDE10A proteins
were also detected in adipose tissue or adipocytes.
Conclusions: Multiple PDE families are present in human adipose tissue and their activities are differentially affected by obesity
and T2D.
Nutrition and Diabetes (2011) 1, e13; doi:10.1038/nutd.2011.9; published online 8 August 2011
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Introduction
The incidence of obesity in the developed world is increasing
at an alarming rate. Concurrent with the increase in the
incidence of obesity is an increase in the incidence of Type 2
diabetes (T2D). It has been reported that over 80% of adults
diagnosed with T2D are obese.
1 The connection between
obesity and the development of T2D has been the focus of
intense research in recent years. It has been demonstrated
that a low-grade, systemic inflammation originating from
adipose tissue is one of the factors associated with systemic
insulin resistance.
2 Adipose tissue secretes numerous adipo-
kines, which have been shown to affect whole body’s insulin
sensitivity and dysregulation of the secretion of these factors
could contribute to the development of insulin resistance in
obesity.
3 Also, excess fatty acids released from the adipocytes
of obese persons contribute to ectopic fat storage in non-
adipose tissues such as liver and muscle, exacerbating their
insulin resistance.
4
Cyclic nucleotide phosphodiesterases (PDEs) regulate in-
tracellular signaling in many different cell types by degrad-
ing cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate (cGMP).
5 There are currently 21
genes, which code for distinct PDE enzymes. The enzymes
can be further divided, based on sequence and chemical
properties, into 11 different families denoted PDE1-11.
5 PDEs
are expressed in virtually all cell types in the body and have
specific roles in the regulation of diverse biological functions
by controlling discrete pools of cyclic nucleotides. Inhibitors
to specific PDE families, such as PDE3 and PDE5 inhibitors,
are currently used in clinical practice.
6,7
In adipocytes, the ability of insulin to antagonize cAMP-
induced lipolysis is mainly due to insulin-induced activation
of PDE3B.
8–9 PDE3B has also been shown to have a role in
calcium-induced anti-lipolysis in human adipocytes.
10
PDE3B has a central role in the regulation of not only
lipolysis but also other biological functions in adipocytes
such as lipogenesis and glucose uptake, as evidenced by Received 4 February 2011; revised 10 June 2011; accepted 24 June 2011
Correspondence: Dr B Omar, Department of Experimental Medical Sciences,
Division of Diabetes, Metabolism and Endocrinology, Lund University,
Biomedical Center C11, So ¨lvegatan 19, Lund SE 211 84, Sweden.
E-mail: bilal.omar@med.lu.se
Citation: Nutrition and Diabetes (2011) 1, e13; doi:10.1038/nutd.2011.9
& 2011 Macmillan Publishers Limited All rights reserved 2044-4052/11
www.nature.com/nutdstudies with PDE3B-deficient mice and PDE3 inhibitors.
11,12
PDE4 is another PDE, which is highly expressed in adipo-
cytes. There are four different isoforms of PDE4, which have
been shown to be expressed in rodent adipocytes;
13 however,
there is little known about their function in adipocytes. A
deletion mutant mouse model of one PDE4 isoform suggests
a potential role in metabolic homeostasis. Mice deficient in
PDE4B show reduced body weight and reduced adipose
tissue mass compared with wild-type animals, and are
resistant to high-fat diet-induced weight gain and adipose
tissue inflammation.
14 Although PDE3B and PDE4 isoforms
appear to comprise most of the PDE activity in rodent
adipocytes, the activity of other PDEs in adipocytes and
adipose tissue have been described. Calcium-inducible
(PDE1) and cGMP inducible (PDE2) PDE activities have been
identified in rat adipocytes.
15,16 PDE5A has been studied in
differentiated human adipocytes, but its expression de-
creases as adipocytes mature.
17 The mRNA expression level
of a number of PDE family members has been recently
determined in a number of rat tissues, including adipose
tissue.
18 Among the PDEs expressed were PDE9A, PDE10A
and PDE11A.
18 The protein regulation and biological func-
tion of these PDEs in adipose tissue are not known at this
time, however, there are indications that some of these
enzymes contribute to the regulation of adipose tissue
homeostasis. Deletion mutant mouse models of PDE9A and
PDE10A display reduced body weight or reduced adipose
tissue mass compared with wild-type mice.
19,20
Although there have been previous reports to changes in
PDE activity in subcutaneous (SC) adipose tissue in patients
with non-insulin-dependent diabetes mellitus,
21 to date
there have been no thorough investigations of PDE expres-
sion and activities in different human adipose tissue depots.
In this study, we investigated PDE expression and activities
in human adipose tissue. We further compared the activities
of PDEs in different adipose tissue depots in non-obese and
obese subjects.
Patients and methods
Patients
Patients with scheduled gastrointestinal surgeries at Ska ˚ne
University Hospital were recruited by the surgeons involved
in the study. Adipose tissue biopsy samples, weighing
0.25–2.5g, were obtained from patients undergoing bariatric
surgery or cholecystectomy operations. The criterion for
acceptance for bariatric surgery was morbid obesity defined
as a body mass index (BMI) greater than 35kgm
 2. In this
study, patients with a BMIX30 were considered obese and
BMIo30 were considered non-obese. Subcutaneous adipose
tissue biopsy samples were obtained from the abdomen and
visceral adipose tissue biopsy samples were obtained from
the greater omentum in each patient after informed consent
was given. Patients were not excluded for any conditions and
a detailed accounting of all pre-existing conditions and
medications taken by the patients was kept for reference. All
experiments were approved by the Regional Ethics Commit-
tee in Lund, Sweden.
Adipocyte isolation
Human adipocytes were isolated by collagenase digestion as
previously described.
22 Adipocytes were diluted in Krebs–
Ringer buffer containing 25mM Hepes, 200nM adenosine,
2m M glucose and 1% bovine serum albumin. Adipocytes
were washed twice in BSA-free Krebs–Ringer buffer and
homogenized in 1.5volumes of a buffer containing 50mM
TES, 2mM EGTA, 1mM EDTA, 250mM sucrose, 40mM
phenylphosphate, 5mM NaF, 1mM dithioerythriol, 0.5mM
sodium orthovanadate, 10mgml
 1 antipain, 10mgml
 1 leu-
peptin, 1mgml
 1 pepstatin A, pH 7.4. Homogenates were
centrifuged at 10000 g for 10min at 41C, the fat cake was
removed and protein concentrations were determined by the
method of Bradford.
23
Immunoblotting
Adipose tissue homogenates were prepared as described
above for adipocytes. Human adipocytes and adipose tissue
homogenates, 20 and 30mg protein, respectively, were
subjected to SDS-PAGE on 7–8% acrylamide gels followed
by transfer to nitrocellulose membranes (GE Healthcare,
Amersham UK). Membranes were blocked in 10% non-fat
dry milk with 0.1% Tween-20 for 1h before overnight
incubation at 41C with primary antibodies (Scottish Biome-
dical, Glasgow, Scotland, UK), as indicated in Results. After
primary antibody incubation, membranes were washed and
incubated with HRP-conjugated secondary antibodies (Thermo
Scientific, Rockford, IL, USA) and diluted in 5% non-fat dry
milk for 1h at room temperature. Chemiluminesence of
immunoreactive bands was obtained using Supersignal West
Pico Stable reagents (Thermo Scientific). Immunoblot images
were captured with an IR-LAS1000 ECL camera (FUJIfilm,
Stamford, CT, USA).
cAMP PDE assay
PDE activities were measured in duplicate in the presence or
absence of the PDE3 inhibitor OPC3911 (Otsuka Pharma-
ceuticals, Tokyo, Japan) or the PDE4 inhibitor Rolipram
(Biomol International, Exeter, UK) as previously described.
24
The assay was performed at 301C for 45min in a total
volume of 300ml of reaction buffer containing 50mM TES,
pH 7.4, 250mM sucrose, 1mM EDTA, 0.1mM EGTA, 8.3mM
MgCl2, 0.5mM cAMP, 1mCiml
 13 H-cAMP and 0.6mgml
 1
ovalbumin. PDE activity was calculated as pmol
3H-cAMP
hydrolyzed per minute per milligram of protein. The PDE3
and PDE4 activities were calculated as the proportion of the
total activity that is inhibited by the PDE3 and PDE4
inhibitors, respectively.
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Data are expressed as the mean±s.e.m. Statistical signifi-
cance was determined using unpaired two-tailed Student’s
t-tests, unless otherwise indicated. Correlation was deter-
mined using Pearson’s correlation coefficient. The differ-
ences were considered statistically significant if Po0.05.
Statistical analysis was performed using Graph Pad Prism
version 4 software (GraphPad Software, La Jolla, CA, USA).
Results
Correlation between PDE activities and BMI in adipose tissue
Analysis of adipose tissue biopsy samples revealed a sig-
nificant inverse correlation between total PDE activity and
BMI in both SC and omental (OM) adipose tissue (Figures 1a
and b). The total PDE activity is the sum of the activities of
several different PDE enzyme families. Selective inhibitors to
PDE3 and PDE4 family enzymes were used to identify PDE3
and PDE4 activities in adipose tissues. In SC adipose tissue,
there was a negative correlation between PDE3 activity and
BMI, which was the strongest correlation of all measured
(Figure 1c). The negative correlation between PDE3 activity
and BMI in OM adipose tissue was also significant
(Figure 1d), as was the negative correlation between PDE4
and BMI in both depots (Supplementary Figures 1a and 1b).
There was a substantial amount of PDE activity remaining
after inhibiting PDE3 and PDE4. The combined activities of
these isoforms are hereafter referred to as PDEn. PDEn
activity was significantly negatively correlated with BMI in
SC adipose tissue (Supplementary Figure 1c), but did not
correlate with BMI in OM adipose tissue (Supplementary
Figure 1d).
PDE activities in adipose tissue: effects of obesity and adipose
tissue depot
PDE activity was investigated with respect to differences in
obesity and between adipose tissue depots. In obese patients,
total PDE, PDE3 and PDE4 activities were significantly
reduced in both OM and SC adipose tissue depots compared
with non-obese patients (Table 1). PDEn activity in SC
adipose tissue from obese patients was significantly lower
than that of non-obese patients (Table 1), whereas no
differences were seen in PDEn activity in OM adipose tissue.
When comparing the SC and OM adipose tissue depots,
non-obese patients had no significant differences in any of
the PDE activities, whereas obese patients had significantly
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Figure 1 Correlation between BMI and PDE activities in adipose tissue. Correlation between BMI and SC (a)( n¼22) or OM (b)( n¼23) adipose tissue total PDE
activity. Correlation between BMI and SC (c)( n¼22) or OM (d)( n¼23) adipose tissue PDE3 activity. The squares of the Pearson correlation coefficients are shown
on each graph.
Table 1 PDE activities in whole adipose tissue
Activity
(pmolmin
 1 per mg)
Non-obese SC
n¼6
Obese SC
n¼16
Non-obese OM
n¼6
Obese OM
n¼17
Total 18.9±4.4 6.7±0.9
a 21.1±4.0 11.7±1.8
b,c
PDE3 9.1±2.3 2.8±0.5
a 8.1±1.5 4.2±0.8
b
PDE4 4.1±1.4 1.7±0.3
d 6.4±1.0 3.4±0.8
c
PDEn 6.3±1.6 2.3±0.5
a 6.1±2.1 3.9±0.5
c
Abbreviations: PDE, phosphodiesterase; OM, omental; SC, subcutaneous.
aNon-obese SC vs obese SC, Po0.01;
bNon-obese OM vs obese OM, Po0.05;
cObese SC vs Obese OM, Po0.05;
dNon-obese SC vs obese SC, Po0.05.
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Nutrition and Diabeteslower total PDE, PDE4 and PDEn activity in SC adipose tissue
compared with OM adipose tissue (Table 1). PDE3 activity
did not differ significantly between depots in obese patients.
PDE activity in patients with T2D
Phosphodiesterase activities were measured in the adipose
tissues of patients with T2D (n¼5) and compared with
patients without diabetes (n¼11) with matching mean BMI.
There was a significant increase in PDEn activity in the SC
adipose tissue of patients with T2D compared with obese
patients without diabetes (Figure 2). This difference was not
seen in OM adipose tissue. There were no other significant
differences in PDE activities when comparing obese T2D
patients with obese patients without diabetes.
PDE activities in isolated adipocytes: effects of obesity and
adipose tissue depot
Adipose tissue not only contains primarily adipocytes but
also a stromal and vascular cell fraction. In a subset of
patients, adipose tissue biopsy samples were used for
isolation of primary adipocytes and measurement of PDE
activities. There were inverse correlations between BMI and
both total PDE (Figure 3b) and PDE3 activities in isolated
adipocytes from OM adipose tissue (Figure 3d). There were
no such correlations in the SC depot (Figures 3a and c).
Furthermore, there were no correlations between BMI and
PDE4 or PDEn activities in adipocytes from OM or SC depots
(data not shown).
There were significantly lower total PDE and PDE3
activities in adipocytes from OM adipose tissue of obese
patients compared with that of non-obese patients (Table 2),
but there were no significant differences in the activities of
PDE4 or PDEn in OM adipocytes, when comparing non-
obese and obese patients (Table 2). When comparing the
different PDE activities in adipocytes from SC adipose tissue
from obese and non-obese patients, no significant differ-
ences were detected (Table 2).
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Figure 2 Comparison of PDEn activitiy in adipose tissue from obese non-
diabetic and T2D patients. PDEn activity in adipose tissue from obese non-
diabetic patients (black bars) (n¼11) compared with T2D patients (white
bars) (n¼4). Data are presented as mean±s.e. *Po0.05.
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Figure 3 Correlation between BMI and PDE activities in primary adipocytes. Correlation between BMI and total PDE activity in SC (a)( n¼15) or OM (b)( n¼20)
primary adipocytes. Correlation between BMI and PDE3 activity in SC (c)( n¼16) or OM (d)( n¼14). The squares of the Pearson correlation coefficients are shown
on each graph.
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Nutrition and DiabetesIn an effort to identify which PDE proteins are expressed in
adipose tissue and adipocytes in addition to PDE3 and 4
isoforms, we made use of antibodies raised against multiple
human PDE isoforms. PDE7B, PDE9A and PDE10A were
detected in homogenates from adipose tissue (Supplemen-
tary Figure 2a), whereas in isolated adipocytes, PDE9A and
PDE10A were detected (Supplementary Figure 2b).
Discussion
This study investigated the activity of PDEs in human
adipose tissue and the differences seen in obesity, T2D and
between adipose tissue depots.
In adipose tissue there was a negative correlation between
PDE activities and BMI. Although the exact effects of
reductions in PDE activities with increasing obesity are not
known, the decreased PDE activities in adipose tissue seen in
obesity might have potential physiological consequences. In
obese subjects the anti-lipolytic effect of insulin is dimin-
ished.
25 PDE3B is the central enzyme controlling the anti-
lipolytic effect of insulin.
26 Thus, decreased PDE3B activity
with increasing obesity, as seen in our study, may be a
contributing factor to the diminished anti-lipolytic effect of
insulin seen in obese patients. Decreased PDE4 activity in the
adipose tissue of obese patients might also have conse-
quences for lipolysis. Decreased PDE4 activities may poten-
tially raise the rate of lipolysis, as seen in rat adipocytes,
12
and lead to an increase in fatty acid release to the circulation.
Excess fatty acids have been shown to interfere with insulin
signaling in liver and skeletal muscle, contributing to the
development of insulin resistance in these tissues.
4
This study also demonstrated that PDE activities other
than PDE3 and PDE4 are present in adipose tissue and
adipocytes. These activities were collectively referred to as
PDEn and were also affected by obesity and T2D. PDEn
activity was unique from PDE3 and PDE4 activity in certain
aspects. PDEn activity was increased in SC adipose tissue
from patients diagnosed with T2D. As PDEn does not include
PDE3B, the only PDE isoform known to be regulated by
insulin, it is not likely that the increased PDE activity reflects
insulin supplementation or endogenous hyperinsulinemia.
However, increased PDEn could reflect some other aspect of
T2D. Further work using selective inhibitors of the PDE
families that potentially contribute to PDEn will need to be
carried out in a larger sample of T2D patients to determine
which PDE families are responsible for this increased activity.
One of the hallmarks of obesity is an increase in the
infiltration of adipose tissue by inflammatory cells, with
visceral adipose tissue being more prone to infiltration than
SC adipose tissue.
27 The consequences of decreased PDE
activities in adipose tissue in obesity could also include
altered states of inflammation. Previous studies have shown
that the PDE3 inhibitor Cilostazol inhibited inflammatory
cytokine expression in cultured adipocytes as well as in the
db/db mouse, a mouse model of T2D.
28 Inhibitors to PDE3
and PDE4 enzymes show anti-inflammatory properties in
certain immune cell types.
29,30 In addition, mice deficient in
the PDE4B protein were shown to have reduced adipose
tissue tumor necrosis factor-a, a marker of inflammation,
when fed a high-fat diet.
14
In an attempt to understand more about the PDEn pool of
PDEs, we performed western blot analysis of some PDEs for
which selective inhibitors are not available. PDE9A and
PDE10A were expressed in adipose tissue as well as in
adipocytes. PDE7B was detected in adipose tissue but not
in isolated adipocytes. Although PDE9 is selective for cGMP,
PDE10 can hydrolyze both cGMP and cAMP.
5 It has been
demonstrated that genetic deficiency of PDE10A in mice
results in decreased body weight, particularly in females.
19
PDE9A deficient mice fed a high-fat diet are reported to have
reduced weight gain and fat mass compared with wild-type
mice.
20 These studies suggest a role for these PDEs in adipose
tissue homeostasis. Furthermore, the presence of a cGMP-
dependent lipolytic pathway, which is stimulated by atrial
natiuretic peptide has been described in human adipo-
cytes.
31 PDE9A and PDE10A might be candidates for the
PDE, responsible for regulating the cGMP pool in adipocytes
associated with atrial natiuretic peptide-induced lipolysis.
In summary, we conclude that PDE activities are reduced
in obesity. Further studies will be performed in order to
connect the altered activity profile of PDEs to different
biological functions and thereby determine whether and
how they have a role in the development of adipose tissue
insulin resistance.
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Table 2 PDE activities in primary adipocytes
Activity
(pmolmin
 1 per mg)
Non-obese SC
n¼6
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Non-obese OM
n¼6
Obese OM
n¼17
Total 35.7±7.5 26.3±7.0 73.6±20.2 21.7±8.4
a
PDE3 31.8±7.2 20.2±7.4 50.0±13.9 15.1±8.2
a
PDE4 6.8±2.7 4.3±1.7 20.5±8.1 5.6±2.5
PDEn 2.4±0.7 4.2±1.7 9.9±4.5 2.5±0.9
Abbreviations: PDE, phosphodiesterase; OM, omental; SC, subcutaneous.
aNon-obese OM vs obese OM, Po0.05.
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